Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP Tariff Task Force Broadly OKs First Proposal
The ruling Liberal Democratic Party’s (LDP) US tariff task force on April 21 broadly agreed on the draft of its first proposal calling for government responses, with the final touches to be added by the party’s policy chief Itsunori Onodera,…
To read the full story
Related Article
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- Japan Will Receive MFN Status on US Drug Tariffs: Akazawa
October 1, 2025
- US Confirms 50% Tariffs on Japan’s Heavy Trucks; Pharma Capped at 15%
September 29, 2025
- Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
September 10, 2025
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
REGULATORY
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…